212 related articles for article (PubMed ID: 26157347)
1. Sensitization of chemo-resistant human chronic myeloid leukemia stem-like cells to Hsp90 inhibitor by SIRT1 inhibition.
Kim HB; Lee SH; Um JH; Kim MJ; Hyun SK; Gong EJ; Oh WK; Kang CD; Kim SH
Int J Biol Sci; 2015; 11(8):923-34. PubMed ID: 26157347
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1.
Kim HB; Lee SH; Um JH; Oh WK; Kim DW; Kang CD; Kim SH
Oncotarget; 2015 Nov; 6(34):36202-18. PubMed ID: 26416354
[TBL] [Abstract][Full Text] [Related]
3. Nonsteroidal Anti-inflammatory Drugs Sensitize CD44-Overexpressing Cancer Cells to Hsp90 Inhibitor Through Autophagy Activation.
Moon HJ; Park SY; Lee SH; Kang CD; Kim SH
Oncol Res; 2019 Jul; 27(7):835-847. PubMed ID: 30982499
[TBL] [Abstract][Full Text] [Related]
4. Hsp90 N- and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells.
Chen C; Zhuang Y; Chen X; Chen X; Li D; Fan Y; Xu J; Chen Y; Wu L
Oncotarget; 2017 Feb; 8(6):10025-10036. PubMed ID: 28036294
[TBL] [Abstract][Full Text] [Related]
5. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.
McCollum AK; TenEyck CJ; Stensgard B; Morlan BW; Ballman KV; Jenkins RB; Toft DO; Erlichman C
Cancer Res; 2008 Sep; 68(18):7419-27. PubMed ID: 18794130
[TBL] [Abstract][Full Text] [Related]
6. Amurensin G, a novel SIRT1 inhibitor, sensitizes TRAIL-resistant human leukemic K562 cells to TRAIL-induced apoptosis.
Kim HB; Kim MJ; Lee SH; Lee JW; Bae JH; Kim DW; Dao TT; Oh WK; Kang CD; Kim SH
Biochem Pharmacol; 2012 Aug; 84(3):402-10. PubMed ID: 22483777
[TBL] [Abstract][Full Text] [Related]
7. HSP90 inhibitor 17-AAG selectively eradicates lymphoma stem cells.
Newman B; Liu Y; Lee HF; Sun D; Wang Y
Cancer Res; 2012 Sep; 72(17):4551-61. PubMed ID: 22751135
[TBL] [Abstract][Full Text] [Related]
8. Amurensin G enhances the susceptibility to tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity of cancer stem-like cells of HCT-15 cells.
Lee SH; Kim MJ; Kim DW; Kang CD; Kim SH
Cancer Sci; 2013 Dec; 104(12):1632-9. PubMed ID: 24118446
[TBL] [Abstract][Full Text] [Related]
9. HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.
Rao R; Fiskus W; Yang Y; Lee P; Joshi R; Fernandez P; Mandawat A; Atadja P; Bradner JE; Bhalla K
Blood; 2008 Sep; 112(5):1886-93. PubMed ID: 18591380
[TBL] [Abstract][Full Text] [Related]
10. Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1.
Oh WK; Cho KB; Hien TT; Kim TH; Kim HS; Dao TT; Han HK; Kwon SM; Ahn SG; Yoon JH; Kim TH; Kim YG; Kang KW
Mol Pharmacol; 2010 Nov; 78(5):855-64. PubMed ID: 20713551
[TBL] [Abstract][Full Text] [Related]
11. Low dose HSP90 inhibition with AUY922 blunts rapid evolution of metastatic and drug resistant phenotypes induced by TGF-β and paclitaxel in A549 cells.
Bacon NA; Larre I; Lawag AA; Merritt C; Smith M; Rosolen M; Sollars VE
Biomed Pharmacother; 2020 Sep; 129():110434. PubMed ID: 32768937
[TBL] [Abstract][Full Text] [Related]
12. Redefining the Phenotype of Heat Shock Protein 90 (Hsp90) Inhibitors.
Wang Y; Koay YC; McAlpine SR
Chemistry; 2017 Feb; 23(9):2010-2013. PubMed ID: 27862436
[TBL] [Abstract][Full Text] [Related]
13. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
Wang W; Zhang J; Li Y; Yang X; He Y; Li T; Ren F; Zhang J; Lin R
Cancer Lett; 2015 Jan; 356(2 Pt B):791-9. PubMed ID: 25449787
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
[TBL] [Abstract][Full Text] [Related]
15. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells.
Lee CH; Hong HM; Chang YY; Chang WW
Biochimie; 2012 Jun; 94(6):1382-9. PubMed ID: 22445681
[TBL] [Abstract][Full Text] [Related]
17. The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-κB and disruption of mitochondria-dependent pathways.
Wang R; Shao F; Liu Z; Zhang J; Wang S; Liu J; Liu H; Chen H; Liu K; Xia M; Wang Y
Chem Biol Interact; 2013 Sep; 205(1):1-10. PubMed ID: 23777986
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol induces apoptosis in K562 (chronic myelogenous leukemia) cells by targeting a key survival protein, heat shock protein 70.
Chakraborty PK; Mustafi SB; Ganguly S; Chatterjee M; Raha S
Cancer Sci; 2008 Jun; 99(6):1109-16. PubMed ID: 18429957
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
20. BAG3-dependent expression of Mcl-1 confers resistance of mutant KRAS colon cancer cells to the HSP90 inhibitor AUY922.
Wang CY; Guo ST; Croft A; Yan XG; Jin L; Zhang XD; Jiang CC
Mol Carcinog; 2018 Feb; 57(2):284-294. PubMed ID: 29068469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
